Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sisram MedicalSRAMF 57 EV-to-EBIT is 4.76 as of Jul. 22, 2026, which is 29% below its 10-year median of 6.70. GuruFocus rates SRAMF with a GF Score™ of 57/100 and a GF Value™ of $0.98 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Sisram Medical ranks better than 92.04% on this metric.
Sisram Medical (OTCPK:SRAMF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sisram Medical's Enterprise Value for the quarter that ended in Dec. 2025 was $396.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sisram Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $31.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sisram Medical EV-to-EBIT Related Terms
Sisram Medical EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sisram Medical's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sisram Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sisram Medical EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sisram Medical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sisram Medical's EV-to-EBIT falls into.
Sisram Medical's current Enterprise Value is $151.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sisram Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $31.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sisram Medical (SRAMF) has a EV-to-EBIT of 4.76 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sisram Medical and its competitors. This is 29% below median its historical median of 6.70. Over the past decade, Sisram Medical's EV-to-EBIT has ranged from 1.09 to 89.81. According to the industry distribution chart, Sisram Medical ranks #37 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 8%.
Is Sisram Medical's EV-to-EBIT too high?
Sisram Medical's current EV-to-EBIT of 4.76 is 29% below median its 10-year median of 6.70. Over the past 10 years, this metric has ranged from a low of 1.09 to a high of 89.81. The Medical Devices & Instruments industry median EV-to-EBIT is 18.28. Sisram Medical's value of 4.76 is 74% below this industry median. Based on the distribution chart, Sisram Medical ranks #37 out of 465 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sisram Medical has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sisram Medical's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sisram Medical ranks #37 out of 465 companies for EV-to-EBIT. This places Sisram Medical in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.28. Sisram Medical's value of 4.76 is 74% below this benchmark. Historically, Sisram Medical's own EV-to-EBIT has ranged from 1.09 to 89.81 over the past decade. While the company's 10-year median is 6.70 vs. the industry median of 18.28, Sisram Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.28, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sisram Medical's current EV-to-EBIT of 4.76 is 74% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sisram Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sisram Medical's current EV-to-EBIT is 4.76, which is 29% below median its own 10-year median of 6.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sisram Medical stock overvalued right now?
Based on GuruFocus' analysis, Sisram Medical (SRAMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.98, compared to a current price of $0.44 — trading 55.3% below its estimated fair value. The current EV-to-EBIT is 4.76, which is 29% below median its 10-year median of 6.70 and 74% below the Medical Devices & Instruments industry median of 18.28. Sisram Medical's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sisram Medical (SRAMF), the current EV-to-EBIT is 4.76 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sisram Medical (SRAMF) Overvalued in 2026?
Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued.
The current stock price of $0.44 is trading 55.3% below its estimated GF Value™ of $0.98.
GuruFocus considers Sisram Medical to be Significantly Undervalued.
Key valuation signals for SRAMF:
EV-to-EBIT: 4.76 (29% below median its 10-year median of 6.70)
GF Value™: $0.98 vs. price of $0.44 (55.3% below fair value)
Industry Position: 74% below the Medical Devices & Instruments median (#37 of 465)
No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
57GF Score
Get the complete analysis for SRAMF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRAMF has been successfully added to your 
